Comparison of intra-articular injection of ArtiAid®-Mini with Ostenil® -Mini for trapeziometacarpal osteoarthritis: A double-blind, prospective, randomized, non-inferiority trial

Objectives: This study aims to compare the effectiveness and safety of intra-articular hyaluronic acid (HA) injections of ArtiAid((R))-Mini (AAM) and Ostenil((R))-Mini (OM) for the treatment of trapeziometacarpal joint osteoarthritis. Patients and methods: Between February 2018 and April 2020, this 24-week, double-blind, prospective, randomized, non-inferiority trial included a total of 17 patients (8 males, 9 females; mean age: 60.3 +/- 9.5 years; range, 42 to 76 years) who were treated with either intra-articular AAM (n=8) or OM (n=9). The primary outcome was pain according to a change in Visual Analog Scale (VAS) at 12 weeks after the last injection. The secondary outcomes included the change of VAS at Weeks 2, 4, and 24 after the injection, satisfaction, range of motion ( ROM) of trapeziometacarpal joint, pinch strength, grip strength, and adverse events at Weeks 2, 4, 12, and 24 after the injection. Results: Eight patients with AAM and eight patients with OM completed the follow-up. No significant differences in primary and secondary outcomes were observed between the two groups at b aseline a nd e ach t ime p oint ( p > 0.05). T he i ntra-group differences were significant in each time point. Conclusion: The intra-articular injection of either AAM or OM is effective and safe for patients with trapeziometacarpal osteoarthritis up to 24 weeks.